|
|
Volumn 9, Issue 2, 2010, Pages 89-92
|
|
2009 FDA drug approvals
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AFREZZA;
BIOLOGICAL PRODUCT;
COMPLEMENT COMPONENT C1S INHIBITOR;
ECALLANTIDE;
EXENDIN 4;
EXTAVIA;
FOLOTYN;
INSULIN;
INTERFERON BETA SERINE;
KALBITOR;
LIRAGLUTIDE;
NEW DRUG;
PRALATREXATE;
RECOMBINANT ANTITHROMBIN III;
RECOMBINANT HUMAN INSULIN;
SAXAGLIPTIN;
UNCLASSIFIED DRUG;
USTEKINUMAB;
WART VIRUS VACCINE;
ANGIONEUROTIC EDEMA;
ANTITHROMBIN III DEFICIENCY;
DIABETES MELLITUS;
DRUG APPROVAL;
DRUG INDICATION;
DRUG INDUSTRY;
DRUG SAFETY;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
LUNG CANCER;
LUNG FUNCTION TEST;
NON INSULIN DEPENDENT DIABETES MELLITUS;
PERIPHERAL T CELL LYMPHOMA;
PRIORITY JOURNAL;
PRODUCTIVITY;
RISK ASSESSMENT;
SHORT SURVEY;
THYROID MEDULLARY CARCINOMA;
BIOLOGICAL PRODUCTS;
DRUG APPROVAL;
DRUG INDUSTRY;
HUMANS;
RISK MANAGEMENT;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 75949085017
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd3101 Document Type: Short Survey |
|
Times cited : (97)
|
|
References (0)
|